Advertisement
Skip to Content

Kelly CRISPR & Gene Editing Tech ETF XDNA

Medalist Rating as of | See Strategic Investment Hub

Morningstar’s Analysis XDNA

Will XDNA outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Kelly CRISPR & Gene Editing Tech ETF’s management team is just average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze. The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings XDNA

  • Current Portfolio Date
  • Equity Holdings 23
  • Bond Holdings 0
  • Other Holdings 3
  • % Assets in Top 10 Holdings 71.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector
14.69
364,900
Healthcare
10.58
262,874
Healthcare
10.50
260,671
Healthcare
8.97
222,822
Healthcare
5.17
128,447
Healthcare
4.64
115,335
Healthcare
4.50
111,752
Healthcare
4.25
105,644
Healthcare
4.21
104,585
Healthcare
4.15
103,019
Healthcare